SLGT2. A new paradigm for treatment of heart failure with reduced ejection fraction
Keywords:
heart failure, SLGT2, systolic heart failure, diastolic heart failureAbstract
Introduction: heart failure is the inability of the heart to pump the blood necessary to provide the metabolic requirements of peripheral tissues and meet the needs of the body. It is a clinical syndrome that represents the terminal stage of several heart diseases. Objective: describe the efficacy and safety of sodium glucose cotransporter (SLGT2) inhibitors in the management of patients with heart failure with reduced ejection fraction. Method: an updated bibliographic review of a descriptive nature was carried out in databases from PubMed, Clinical Key, Google Scholar, Medline, Cochrane Library, Web ofScience and Scopus, and information from high-impact journals and randomized clinical studies was also included. Key words such as: “heart failure”, “SLGT2”, “systolic heart failure”, “diastolic heart failure” were used for the search. Publications from the last 5 years were proposed as inclusion criteria. Development: sodium glucose cotransporter type 2 inhibitors contribute to the reduction of hospitalizations in patients with heart failure with reduced ejection fraction when they are administered in conjunction with the standard treatment for this pathology, that is, when the therapy consists of the four pillars to treat the disease. Conclusion: SGLT2 are new antihyperglycemic agents that have demonstrated safety and efficacy in terms of reducing cardiovascular mortality and hospitalizations in patients with heart failure.
Downloads
References
Salinas-Lezama E, Seniscal-Arredondo D, Alarcón-Sotelo A. Efectos nefrológicos de los SGLT2. ¿Qué sabemos hasta ahora? Med Interna México. 2019;
Uso de iSGLT2 en pacientes en tratamiento con antraciclinas - Sociedad Española de Cardiología [Internet]. [citado 29 de marzo de 2023]. Disponible en: https://secardiologia.es/blog/13655-uso-de-isglt2-en-pacientes-en-tratamiento-con-antraciclinas
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-56.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. diciembre de 2020;17(12):761-72.
Buitrago Sandoval AF, Sánchez Vallejo CA. Mecanismos de acción de los inhibidores de cotransportador de sodio y glucosa tipo 2 —SGLT2—: Más allá del control de la glicemia. Rev Colomb Cardiol. 1 de marzo de 2020;27:22-5.
Pharmacologic therapy of heart failure with reduced ejection fraction: Mechanisms of action - UpToDate [Internet]. [citado 29 de marzo de 2023]. Disponible en: https://www.uptodate.com/contents/pharmacologic-therapy-of-heart-failure-with-reduced-ejection-fraction-mechanisms-of-action#H1477340059
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 8 de octubre de 2020;383(15):1413-24.
Nelinson DS, Sosa JM, Chilton RJ. SGLT2 inhibitors: a narrative review of efficacy and safety. J Osteopath Med. 1 de febrero de 2021;121(2):229-39.
Agentes diuréticos | Farmacología básica y clínica, 15e | AccessMedicina | McGraw Hill Medical [Internet]. [citado 29 de marzo de 2023]. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?bookid=3038§ionid=255851467
Hernández Rodríguez J, Arnold Domínguez Y, Moncada Espinal OM, Hernández Rodríguez J, Arnold Domínguez Y, Moncada Espinal OM. Los inhibidores del cotransportador sodio-glucosa tipo 2 en el tratamiento de la diabetes mellitus. Rev Cuba Endocrinol [Internet]. diciembre de 2020 [citado 29 de marzo de 2023];31(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1561-29532020000300012&lng=es&nrm=iso&tlng=es
Joshi SS, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart Br Card Soc. 26 de febrero de 2021;107(13):1032-8.
Almero-Ballesteros B, Tarraga-Marcos L, Madrona-Marcos F, Romero-de Avila JM, TárragaLópez PJ, Almero-Ballesteros B, et al. Diabetes e insuficiencia cardiaca. ¿Son los inhibidores del cotransportador de sodioglucosa tipo dos el futuro del tratamiento? J Negat No Posit Results. junio de 2022;7(2):209-34.
Hormonas pancreáticas y fármacos hipoglucemiantes | Farmacología básica y clínica, 15e | AccessMedicina | McGraw Hill Medical [Internet]. [citado 29 de marzo de 2023]. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?bookid=3038§ionid=256841045
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol. 23 de marzo de 2021;77(11):1381-92.
Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs Context. 28 de febrero de 2020;9:2019-11-3.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 21 de noviembre de 2019;381(21):1995-2008.
Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovasc Diabetol. 4 de octubre de 2019;18(1):129.
Published
How to Cite
Issue
Section
ARK
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Gaceta Médica Estudiantil magazine provides immediate Open Access to its content. It is published under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC) license, which allows sharing (copying and redistributing the material in any medium or format) and adapting (remixing, transforming, and building upon the material), under the terms of acknowledge authorship and not make commercial use of the materials.
